146 related articles for article (PubMed ID: 1976775)
21. Plasma dapsone and its metabolite monoacetyldapsone levels in leprotic patients.
Garg SK; Kumar B; Bakaya V; Lal R; Shukla VK; Kaur S
Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):552-4. PubMed ID: 3243659
[TBL] [Abstract][Full Text] [Related]
22. Curcumin could prevent methemoglobinemia induced by dapsone in rats.
Bergamaschi MM; Alcantara GK; Valério DA; Queiroz RH
Food Chem Toxicol; 2011 Jul; 49(7):1638-41. PubMed ID: 21426920
[TBL] [Abstract][Full Text] [Related]
23. Carbaryl metabolism is inhibited by cimetidine in the isolated perfused rat liver and in man.
Ward SA; May DG; Heath AJ; Branch RA
J Toxicol Clin Toxicol; 1988; 26(5-6):269-81. PubMed ID: 3143015
[TBL] [Abstract][Full Text] [Related]
24. N-acetylation polymorphism of dapsone in a Japanese population.
Horai Y; Ishizaki T
Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
[TBL] [Abstract][Full Text] [Related]
25. An investigation of the role of metabolism in dapsone-induced methaemoglobinaemia using a two compartment in vitro test system.
Tingle MD; Coleman MD; Park BK
Br J Clin Pharmacol; 1990 Dec; 30(6):829-38. PubMed ID: 2288829
[TBL] [Abstract][Full Text] [Related]
26. Dapsone induces oxidative stress and impairs antioxidant defenses in rat liver.
Veggi LM; Pretto L; Ochoa EJ; Catania VA; Luquita MG; Taborda DR; Sánchez Pozzi EJ; Ikushiro S; Coleman MD; Roma MG; Mottino AD
Life Sci; 2008 Aug; 83(5-6):155-63. PubMed ID: 18602405
[TBL] [Abstract][Full Text] [Related]
27. The methaemoglobin forming and GSH depleting effects of dapsone and monoacetyl dapsone hydroxylamines in human diabetic and non-diabetic erythrocytes in vitro.
Coleman MD; Holden LJ
Environ Toxicol Pharmacol; 2004 May; 17(1):55-9. PubMed ID: 21782713
[TBL] [Abstract][Full Text] [Related]
28. Disposition of dapsone and monoacetyldapsone in rats.
Gordon GR; Peters JH; Ghoul DC; Murray JF; Levy L; Biggs JT
Proc Soc Exp Biol Med; 1975 Nov; 150(2):485-92. PubMed ID: 1208566
[TBL] [Abstract][Full Text] [Related]
29. Cimetidine and omeprazole do not affect cyclosporine disposition by the rat liver.
Bar-Meir S; Bardan E; Ronen I; Krepel Z; Garti M
Eur J Drug Metab Pharmacokinet; 1993; 18(4):355-8. PubMed ID: 8020534
[TBL] [Abstract][Full Text] [Related]
30. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse drug reactions.
Reilly TP; Woster PM; Svensson CK
J Pharmacol Exp Ther; 1999 Mar; 288(3):951-9. PubMed ID: 10027831
[TBL] [Abstract][Full Text] [Related]
31. Cimetidine and omeprazole have different effects on hepatic extraction of lidocaine in rats.
Bruck R; Krepel Z; Bar-Meir S
Gastroenterology; 1990 Sep; 99(3):857-9. PubMed ID: 2379789
[TBL] [Abstract][Full Text] [Related]
32. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
Edstein MD; Rieckmann KH; Veenendaal JR
Br J Clin Pharmacol; 1990 Aug; 30(2):259-65. PubMed ID: 2206787
[TBL] [Abstract][Full Text] [Related]
33. The effect of pregnenolone 16alpha-carbonitrile on the pharmacokinetics and metabolism of dapsone in rats.
Lu M; Poloyac SM; McNamara PJ; Blouin RA
J Pharm Pharmacol; 1999 Jul; 51(7):803-10. PubMed ID: 10467955
[TBL] [Abstract][Full Text] [Related]
34. Dapsone-induced hemolytic anemia: effect of N-hydroxy dapsone on the sulfhydryl status and membrane proteins of rat erythrocytes.
Grossman SJ; Simson J; Jollow DJ
Toxicol Appl Pharmacol; 1992 Dec; 117(2):208-17. PubMed ID: 1471153
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic observations on dapsone in dermatitis herpetiformis.
Swain AF; Ahmad RA; Rogers HJ; Leonard JN; Fry L
Br J Dermatol; 1983 Jan; 108(1):91-8. PubMed ID: 6821646
[TBL] [Abstract][Full Text] [Related]
36. Dapsone in saliva and plasma of man.
Peters JH; Murray JF; Gordon GR; Gelber RH
Pharmacology; 1981; 22(3):162-71. PubMed ID: 7208598
[TBL] [Abstract][Full Text] [Related]
37. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.
Harvey VJ; Slevin ML; Dilloway MR; Clark PI; Johnston A; Lant AF
Br J Clin Pharmacol; 1984 Sep; 18(3):421-30. PubMed ID: 6487480
[TBL] [Abstract][Full Text] [Related]
38. Acedapsone treatment of leprosy patients: response versus drug disposition.
Peters JH; Murray JF; Gordon GR; Levy L; Russell DA; Scott GC; Vincin DR; Shepard CC
Am J Trop Med Hyg; 1977 Jan; 26(1):127-36. PubMed ID: 842774
[TBL] [Abstract][Full Text] [Related]
39. N-acetylation phenotyping using dapsone in a Jordanian population.
Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM
Br J Clin Pharmacol; 1991 Sep; 32(3):289-93. PubMed ID: 1777365
[TBL] [Abstract][Full Text] [Related]
40. Dapsone-induced cholestasis and impairment of bile salt output in the rat.
Veggi LM; Crocenzi FA; Roma MG; Dawson PA; Pellegrino JM; Sánchez Pozzi EJ; Mottino AD
Biochem Pharmacol; 2002 Apr; 63(8):1553-63. PubMed ID: 11996898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
